154 related articles for article (PubMed ID: 38372203)
1. Myxovirus resistance protein A (MxA) expression in myositides: Sarcoplasmic expression is common in both dermatomyositis and lupus myositis.
Xing C; Trivedi J; Bitencourt N; Burns DK; Reisch JS; Cai C
Muscle Nerve; 2024 May; 69(5):548-555. PubMed ID: 38372203
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic potential of sarcoplasmic myxovirus resistance protein A expression in subsets of dermatomyositis.
Uruha A; Allenbach Y; Charuel JL; Musset L; Aussy A; Boyer O; Mariampillai K; Landon-Cardinal O; Rasmussen C; Bolko L; Maisonobe T; Leonard-Louis S; Suzuki S; Nishino I; Stenzel W; Benveniste O
Neuropathol Appl Neurobiol; 2019 Aug; 45(5):513-522. PubMed ID: 30267437
[TBL] [Abstract][Full Text] [Related]
3. Sarcoplasmic MxA expression: A valuable marker of dermatomyositis.
Uruha A; Nishikawa A; Tsuburaya RS; Hamanaka K; Kuwana M; Watanabe Y; Suzuki S; Suzuki N; Nishino I
Neurology; 2017 Jan; 88(5):493-500. PubMed ID: 28039312
[TBL] [Abstract][Full Text] [Related]
4. Sarcoplasmic Myxovirus Resistance Protein A: A Study of Expression in Idiopathic Inflammatory Myopathy.
Waisayarat J; Wongsuwan P; Tuntiseranee K; Waisayarat P; Dejthevaporn C; Khongkhatithum C; Soponkanaporn S
J Inflamm Res; 2023; 16():5417-5426. PubMed ID: 38026261
[TBL] [Abstract][Full Text] [Related]
5. Nailfold videocapillaroscopy alterations in dermatomyositis, antisynthetase syndrome, overlap myositis, and immune-mediated necrotizing myopathy.
Soubrier C; Seguier J; Di Costanzo MP; Ebbo M; Bernit E; Jean E; Veit V; Swiader L; Salort-Campana E; Attarian S; De Paula AM; Kaplanski G; Durand JM; Harlé JR; Schleinitz N
Clin Rheumatol; 2019 Dec; 38(12):3451-3458. PubMed ID: 31440919
[TBL] [Abstract][Full Text] [Related]
6. The host defense peptide LL-37 a possible inducer of the type I interferon system in patients with polymyositis and dermatomyositis.
Lu X; Tang Q; Lindh M; Dastmalchi M; Alexanderson H; Popovic Silwerfeldt K; Agerberth B; Lundberg IE; Wick C
J Autoimmun; 2017 Mar; 78():46-56. PubMed ID: 28012697
[TBL] [Abstract][Full Text] [Related]
7. Expression of myxovirus-resistance protein A: a possible marker of muscle disease activity and autoantibody specificities in juvenile dermatomyositis.
Soponkanaporn S; Deakin CT; Schutz PW; Marshall LR; Yasin SA; Johnson CM; Sag E; Tansley SL; McHugh NJ; Wedderburn LR; Jacques TS
Neuropathol Appl Neurobiol; 2019 Jun; 45(4):410-420. PubMed ID: 29770465
[TBL] [Abstract][Full Text] [Related]
8. Quantitative whole-body muscle MRI in idiopathic inflammatory myopathies including polymyositis with mitochondrial pathology: indications for a disease spectrum.
Zierer LK; Naegel S; Schneider I; Kendzierski T; Kleeberg K; Koelsch AK; Scholle L; Schaefer C; Naegel A; Zierz S; Otto M; Stoltenburg-Didinger G; Kraya T; Stoevesandt D; Mensch A
J Neurol; 2024 Jun; 271(6):3186-3202. PubMed ID: 38438820
[TBL] [Abstract][Full Text] [Related]
9. Contribution of Complement, Microangiopathy and Inflammation in Idiopathic Inflammatory Myopathies.
Honda M; Shimizu F; Sato R; Nakamori M
J Neuromuscul Dis; 2024; 11(1):5-16. PubMed ID: 38143369
[TBL] [Abstract][Full Text] [Related]
10. Autophagy markers LC3 and p62 accumulate in immune-mediated necrotizing myopathy.
Girolamo F; Lia A; Annese T; Giannini M; Amati A; D'Abbicco D; Tampoia M; Virgintino D; Ribatti D; Serlenga L; Iannone F; Trojano M
Muscle Nerve; 2019 Sep; 60(3):315-327. PubMed ID: 31172530
[TBL] [Abstract][Full Text] [Related]
11. Absence of sarcoplasmic myxovirus resistance protein A (MxA) expression in antisynthetase syndrome in a cohort of 194 cases.
Inoue M; Tanboon J; Okubo M; Theerawat K; Saito Y; Ogasawara M; Indrawati LA; Uruha A; Okiyama N; Fujimoto M; Suzuki S; Nishino I
Neuropathol Appl Neurobiol; 2019 Aug; 45(5):523-524. PubMed ID: 30959571
[No Abstract] [Full Text] [Related]
12. Machine learning algorithms reveal unique gene expression profiles in muscle biopsies from patients with different types of myositis.
Pinal-Fernandez I; Casal-Dominguez M; Derfoul A; Pak K; Miller FW; Milisenda JC; Grau-Junyent JM; Selva-O'Callaghan A; Carrion-Ribas C; Paik JJ; Albayda J; Christopher-Stine L; Lloyd TE; Corse AM; Mammen AL
Ann Rheum Dis; 2020 Sep; 79(9):1234-1242. PubMed ID: 32546599
[TBL] [Abstract][Full Text] [Related]
13. Immune-mediated necrotizing myopathy (IMNM): A myopathological challenge.
Merlonghi G; Antonini G; Garibaldi M
Autoimmun Rev; 2022 Feb; 21(2):102993. PubMed ID: 34798316
[TBL] [Abstract][Full Text] [Related]
14. Where are we moving in the classification of idiopathic inflammatory myopathies?
Tanboon J; Uruha A; Stenzel W; Nishino I
Curr Opin Neurol; 2020 Oct; 33(5):590-603. PubMed ID: 32852298
[TBL] [Abstract][Full Text] [Related]
15. Updates on the Immunopathology in Idiopathic Inflammatory Myopathies.
Uruha A; Goebel HH; Stenzel W
Curr Rheumatol Rep; 2021 Jul; 23(7):56. PubMed ID: 34212266
[TBL] [Abstract][Full Text] [Related]
16. The pattern of MHC class I expression in muscle biopsies from patients with myositis and other neuromuscular disorders.
Milisenda JC; Pinal-Fernandez I; Lloyd TE; Grau-Junyent JM; Christopher-Stine L; Corse AM; Mammen AL
Rheumatology (Oxford); 2023 Sep; 62(9):3156-3160. PubMed ID: 36707996
[TBL] [Abstract][Full Text] [Related]
17. The role of interferons type I, II and III in myositis: A review.
Bolko L; Jiang W; Tawara N; Landon-Cardinal O; Anquetil C; Benveniste O; Allenbach Y
Brain Pathol; 2021 May; 31(3):e12955. PubMed ID: 34043262
[TBL] [Abstract][Full Text] [Related]
18. Dermatomyositis: Muscle Pathology According to Antibody Subtypes.
Tanboon J; Inoue M; Saito Y; Tachimori H; Hayashi S; Noguchi S; Okiyama N; Fujimoto M; Nishino I
Neurology; 2022 Feb; 98(7):e739-e749. PubMed ID: 34873015
[TBL] [Abstract][Full Text] [Related]
19. Identification of distinctive interferon gene signatures in different types of myositis.
Pinal-Fernandez I; Casal-Dominguez M; Derfoul A; Pak K; Plotz P; Miller FW; Milisenda JC; Grau-Junyent JM; Selva-O'Callaghan A; Paik J; Albayda J; Christopher-Stine L; Lloyd TE; Corse AM; Mammen AL
Neurology; 2019 Sep; 93(12):e1193-e1204. PubMed ID: 31434690
[TBL] [Abstract][Full Text] [Related]
20. SIGLEC1 enables straightforward assessment of type I interferon activity in idiopathic inflammatory myopathies.
Graf M; von Stuckrad SL; Uruha A; Klotsche J; Zorn-Pauly L; Unterwalder N; Buttgereit T; Krusche M; Meisel C; Burmester GR; Hiepe F; Biesen R; Kallinich T; Stenzel W; Schneider U; Rose T
RMD Open; 2022 Feb; 8(1):. PubMed ID: 35177553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
